Vitruvius Therapeutics gets FDA nod for generic Amicar

Press enter to search
Close search
Open Menu

Vitruvius Therapeutics gets FDA nod for generic Amicar

By Sandra Levy - 12/18/2018
Vitruvius Therapeutics recently received approval from the Food and Drug Administration for its generic Amicar (aminocaproic acid) in 500-mg and 1000-mg dosage strength.

Aminocaproic acid is 6-aminohexanoic acid, which acts as an inhibitor of fibrinolysis.

The product is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.

“We are pleased to improve patient access to this important medicine by offering it immediately through all channels of distribution,” Vitruvius executive vice president of sales and distributions Bryce Harvey said.

Aminocaproic acid tablets had a market value of approximately $26.2 million, in the 12 months ending September 2018, according to IQVIA.

Related Topics